Topics

Pfizer Ends Pact With GlycoMimetics After SCD Failure

05:31 EST 12 Feb 2020 | SCRIP

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a...

      

Related Stories

 

Original Article: Pfizer Ends Pact With GlycoMimetics After SCD Failure

NEXT ARTICLE

More From BioPortfolio on "Pfizer Ends Pact With GlycoMimetics After SCD Failure"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...